Analysts Set Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Target Price at $12.67

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been given an average rating of “Hold” by the six analysts that are presently covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $9.40.

Several equities analysts have recently commented on RXRX shares. Jefferies Financial Group lowered their price target on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Tuesday, September 3rd. KeyCorp lowered their price target on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. Needham & Company LLC lowered their price target on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a research report on Wednesday, September 4th. Finally, Leerink Partners lowered their price target on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd.

Insider Activity at Recursion Pharmaceuticals

In related news, CEO Christopher Gibson sold 20,000 shares of the stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $6.04, for a total value of $120,800.00. Following the completion of the transaction, the chief executive officer now owns 762,656 shares in the company, valued at approximately $4,606,442.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Christopher Gibson sold 20,000 shares of the stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $6.04, for a total value of $120,800.00. Following the completion of the transaction, the chief executive officer now owns 762,656 shares in the company, valued at approximately $4,606,442.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Blake Borgeson sold 11,447 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $6.27, for a total transaction of $71,772.69. Following the completion of the transaction, the director now owns 7,121,322 shares of the company’s stock, valued at approximately $44,650,688.94. The disclosure for this sale can be found here. Insiders sold 231,682 shares of company stock worth $1,711,117 in the last 90 days. Corporate insiders own 15.75% of the company’s stock.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several large investors have recently made changes to their positions in RXRX. Benjamin F. Edwards & Company Inc. bought a new position in shares of Recursion Pharmaceuticals during the 1st quarter valued at about $26,000. National Bank of Canada FI boosted its position in shares of Recursion Pharmaceuticals by 90.9% during the 4th quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock valued at $31,000 after purchasing an additional 1,500 shares in the last quarter. First Horizon Advisors Inc. bought a new position in shares of Recursion Pharmaceuticals during the 4th quarter valued at about $47,000. GAMMA Investing LLC lifted its stake in Recursion Pharmaceuticals by 1,588.4% during the second quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock valued at $48,000 after buying an additional 6,036 shares in the last quarter. Finally, Amalgamated Bank lifted its stake in Recursion Pharmaceuticals by 52.4% during the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after buying an additional 2,459 shares in the last quarter. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Stock Up 3.4 %

Shares of NASDAQ:RXRX opened at $6.12 on Tuesday. The stock has a market capitalization of $1.72 billion, a price-to-earnings ratio of -3.82 and a beta of 0.82. Recursion Pharmaceuticals has a 1-year low of $4.97 and a 1-year high of $15.74. The company’s fifty day moving average is $7.30 and its two-hundred day moving average is $8.74. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.07 and a current ratio of 6.07.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). The business had revenue of $14.42 million for the quarter, compared to analyst estimates of $11.96 million. Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The firm’s revenue for the quarter was up 30.9% on a year-over-year basis. During the same period last year, the company posted ($0.38) earnings per share. Equities analysts anticipate that Recursion Pharmaceuticals will post -1.58 EPS for the current year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.